Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lyell Immunopharma's price to sales ratio was 9.5× on Jan 31, 2024, against 20.8× a year earlier. Over the last 3 years it ranged from 6.0× to 445.5×, with a median of 28.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 9.5× | −0.6 |
| 2023 | Dec 29, 2023 | 10.1× | −12.0 |
| 2022 | Dec 30, 2022 | 22.1× | −160.9 |
| 2021 | Dec 31, 2021 | 183.0× | – |
See a number that looks wrong?